Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Tr Long

Karyopharm Therapeutics Inc.NASDAQ

Description

⋅ Dec 18, 2020 5:39 PM

KPTI: Karyopharm Therapeutics Inc.
2020-12-18 11:30:00
Karyopharm Announces FDA Approval of XPOVIO® (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy

Beyond Technical Analysis